Big Gain For Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI:NASDAQ) rocketted at $3.71, representing a gain of 48.4%. On Fri 13 Mar 20, TRVI:NASDAQ touched a New 2-Week Low of $2.5. The stock appeared on our News Catalysts scanner on Thu 20 Feb 20 at 05:27 PM in the 'MISCELLANEOUS' category. From Fri 28 Feb 20, the stock recorded 22.22% Up Days and 40.00% Green Days
About Trevi Therapeutics, Inc. (TRVI:NASDAQ)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Top 10 Gainers:
- OpGen, Inc. (OPGN:NASDAQ), 101%
- Waitr Holdings Inc. (WTRH:NASDAQ), 74.98%
- Blue Apron Holdings, Inc. (APRN:NYSE), 67.54%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 48.4%
- Vapotherm, Inc. (VAPO:NYSE), 41.71%
- Newgioco Group, Inc. (NWGI:NASDAQ), 40.85%
- VelocityShares 3x Inverse Silver ETN Linked to the S&P GSCI Silver Index ER (DSLV:NASDAQ), 38.36%
- Aytu BioScience, Inc. (AYTU:NASDAQ), 37.39%
- CHF Solutions, Inc. (CHFS:NASDAQ), 33.33%
- ProShares UltraPro Short QQQ (SQQQ:NASDAQ), 32.74%